Therefore, novel agents having greater specificity for HER2 inhibition while excluding EGFR may overcome the resiliency of the HER2/HER3 pathway in HER2-activated cancers and improve the clinical response rates versus conventional HER2 TKIs. This evidence concerns the gene EGFR and cancer.